GlassScriptPhysician profile
Matthew Logan Abbott
NPI 1417572959
$2,142.38
in general payments reported to CMS, 2019-2025
36 companies · $373 in 2025
The $373 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $45.80 · 2021: $391 · 2022: $579 · 2023: $458 · 2024: $296 · 2025: $373.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,127.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $595.92 | 2022-2024 | Briviact |
| Imperative Care, INC | $151.86 | 2025 | Zoom 88-T Large Distal Platform |
| Livanova USA, INC. | $151.74 | 2021-2022 | |
| Sk Life Science, INC. | $100.73 | 2021-2023 | |
| Jazz Pharmaceuticals INC. | $89.76 | 2022 | |
| Alnylam Pharmaceuticals INC. | $76.34 | 2023-2025 | Amvuttra, Onpattro |
| Neurelis, INC. | $75.14 | 2021-2024 | Valtoco |
| Depuy Synthes Sales INC. | $71.25 | 2024-2025 | Cerenovus Enterprise |
| Greenwich Biosciences, INC. | $65.78 | 2020-2021 | |
| Abbvie INC. | $65.72 | 2022-2024 | |
| Ipsen Biopharmaceuticals, INC | $56.28 | 2022-2023 | Dysport |
| Nevro Corp. | $55.19 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $54.95 | 2021-2023 | Ultomiris |
| Takeda Pharmaceuticals U.S.A., INC. | $43.11 | 2024 | Hyqvia |
| Merz Pharmaceuticals, LLC | $42.01 | 2022-2025 | Xeomin, Inbrija |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $39.40 | 2022-2024 | Ingrezza |
| Genzyme Corporation | $35.48 | 2021 | |
| Emd Serono, INC. | $28.99 | 2023 | |
| Allergan, INC. | $28.59 | 2020-2021 | |
| Neuropace, INC. | $28.53 | 2023 | |
| Baxter Healthcare | $24.16 | 2023 | Floseal |
| Hospira, INC. | $23.00 | 2023 | |
| Qapel Medical INC | $22.78 | 2025 | |
| Biohaven Pharmaceuticals, INC. | $21.05 | 2021 | |
| Stryker Corporation | $20.73 | 2025 | Flowtriever |
| Argenx US, INC. | $19.38 | 2025 | Vyvgart Hytrulo |
| Zimmer Biomet Holdings, INC. | $18.96 | 2025 | Thinflap |
| Teva Pharmaceuticals USA, INC. | $16.91 | 2024 | Austedo Xr |
| Astrazeneca Pharmaceuticals LP | $16.39 | 2022 | |
| Pfizer INC. | $15.70 | 2021 | |
| Ns Pharma, INC. | $15.41 | 2023 | Viltepso |
| Janssen Biotech, INC. | $14.74 | 2025 | |
| Amneal Pharmaceuticals LLC | $14.42 | 2023 | Lyvispah |
| Novocure INC. | $14.17 | 2022 | |
| Sunovion Pharmaceuticals INC. | $14.05 | 2021 | |
| Chiesi USA, INC. | $13.76 | 2025 | Cleviprex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Abbott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.